1 Min Read
* LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES THE TREATMENT OF FIRST PATIENT IN GIAPREZA (ANGIOTENSIN II) PEDIATRIC STUDY Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.